Laurus Labs

What Laurus Labs does

Laurus Labs Limited is a Hyderabad-based, publicly listed pharmaceutical manufacturer founded in 2005 that operates an integrated value chain spanning active pharmaceutical ingredient (API) development, finished dosage form manufacturing, and contract development and manufacturing (CDMO) services. The company is a global leader in anti-retroviral (ARV) APIs and operates 15 manufacturing sites across approximately 230 acres in Visakhapatnam with 8,200+ kiloliters of reactor capacity and 12 billion tablet/capsule annual capacity. Its portfolio is organized across five segments: pharmaceutical ingredients (ARV, oncology, cardiovascular, diabetes APIs), finished dosages, biologics and biotechnology (through subsidiary Laurus Bio's precision fermentation), non-human ingredients (animal health and agrochemicals through Laurus Synthesis), and rare disease therapeutics marketed in India under brands including TriLaWil, LASINONE, AMMOBULA, and Larglustat.

Laurus derives revenue through multiple streams: CDMO services for global pharmaceutical innovators, generic API and intermediate supply, finished dosage commercialization via wholly-owned subsidiaries (Laurus Generics Inc. for the US, Laurus Generics GmbH for the EU, Laurus Generics SA for Africa), participation in international pharmaceutical tenders (notably the Global Fund for ARV supply), and dedicated contract manufacturing for animal health and agrochemical companies. The company holds USFDA, WHO, EMA, UK MHRA, TGA, ANVISA, and KFDA certifications, with 1,400+ quality audits completed across facilities. In FY26, Laurus reported revenue of ₹6,813 crore (23% YoY growth), EBITDA of ₹1,826 crore (26.8% margin), and net profit of ₹889 crore (148% YoY growth), with CDMO revenue specifically growing 36% to ₹2,080 crore.

The company's go-to-market combines direct enterprise sales engagement with global pharmaceutical innovators for CDMO contracts, channel partnerships through its generics subsidiaries, and participation in institutional procurement tenders. It has expanded into advanced therapies through investments in ImmunoACT (CAR-T cell therapy, ~33.86% stake) and an IIT Kanpur collaboration for AAV gene therapy, and has committed ₹3,000 crore in capex over two years primarily for CDMO, peptides, fermentation, and advanced therapy capacity, with a stated goal of CDMO reaching 50% of revenue by FY29.

Name

Laurus Labs

Legal name

Laurus Labs Limited

Website

https://lauruslabs.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Laurus Labs is a Hyderabad-based, publicly listed pharmaceutical manufacturer offering integrated API manufacturing, finished dosages, and CDMO services to global pharmaceutical innovators and generic drug companies across 15 manufacturing sites, with growing presence in biologics, cell/gene therapy, and rare disease therapeutics.

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices16 records

Markets served

Revenue model

1. CDMO (Contract Development and Manufacturing): Provides end-to-end contract manufacturing services to global pharmaceutical companies including chemical process development, API manufacturing, and finished dosage form manufacturing. Revenue grew 36% to ₹2,080 crore in FY26, targeting 50% revenue contribution by FY29.
2. Generic APIs and Intermediates: Manufactures and supplies generic active pharmaceutical ingredients including anti-retrovirals, oncology, cardiovascular, and diabetes therapies to global markets.
3. Finished Dosage Forms (Generics): Vertically integrated formulation manufacturing with 10 billion unit capacity for solid oral dosages, serving US, EU, and emerging markets through subsidiary companies.
4. Anti-retroviral (ARV) Products: Global leader in ARV APIs and intermediates, with strategic partnership with Global Fund for supply of combination HIV medications to developing nations.
5. Biologics and Biotechnology: Through Laurus Bio subsidiary - precision fermentation CDMO services for recombinant proteins, growth factors, and cell-culture media for healthcare, food, nutrition markets.
6. Rare Disease Therapeutics: Manufactures and commercializes specialty drugs for Wilson's disease, Tyrosinemia, urea cycle disorders, and Gaucher disease in Indian market.
7. Non-Human Ingredients (Animal Health & Agrochemicals): Through Laurus Synthesis - dedicated CDMO services for animal health ingredients and agrochemical active ingredients from separate manufacturing facilities.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Laurus Labs is a publicly listed Indian pharmaceutical manufacturer headquartered in Hyderabad, India, founded in 2005. The company manufactures and supplies active pharmaceutical ingredients (APIs), finished dosage formulations, and biopharmaceutical products, and also provides contract development and manufacturing organization (CDMO) services to global pharmaceutical customers.

Product overview

Laurus Labs is a research-driven pharmaceutical manufacturing organization offering an integrated portfolio of products and services. The company operates across five core product segments: Pharmaceutical Ingredients (APIs including anti-retroviral, oncology, cardiovascular APIs), Finished Dosages (oral solid dosages with 10 billion unit capacity), Biologics & Biotechnology (through subsidiary Laurus Bio), Non-Human Ingredients (Animal Health and Agrochemicals), and Rare Disease Therapeutics (TriLaWil, LASINONE, AMMOBULA, Larglustat). The company provides CDMO services through Laurus Synthesis and global reach via subsidiaries Laurus Generics GmbH (Europe) and Laurus Generics Inc. (USA). The business model combines in-house API development with contract manufacturing services for global pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• TriLaWil: Trientine Tetrahydrochloride 333mg - treatment for Wilson's disease
• LASINONE
• AMMOBULA
• Larglustat

Quantifiable outcome

• CDMO revenue grew 36% to ₹2,080 crore in FY26
• +4 more outcomes

Named customers7 records

Segments5 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• KRKA Pharma Private LimitedcoreStrategic or Co-development Partner · 25 January 2024Joint venture agreement for generic formulations development and commercialization in Indian market, leveraging combined capabilities in API manufacturing and formulation development.
• IIT Kanpur (Department of Biological Sciences and Bioengineering)coreStrategic or Co-development Partner · 19 June 2023Memorandum of Agreement for novel gene therapy assets development. Collaboration focuses on AAV vector technology and other gene therapy platforms for treating unmet medical needs in India.
• MPP (Medicine Patent Pool)coreStrategic or Co-development Partner · 21 November 2021Agreement to manufacture Molnupiravir, oral COVID-19 antiviral medication, expanding access to COVID treatments in developing markets.
• ImmunoACT (Immuno-adoptive Cell Therapy Private Limited)coreStrategic or Co-development Partner · 19 November 2021CAR-T cell therapy company in which Laurus holds substantial minority stake (~33.86%). ImmunoACT is developing India's first CART therapy for blood cancers and benefits from Laurus investments in 2021 and 2023.
• Unitaid and Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 14 September 2021Agreement to accelerate development of best-in-class second- and third-line HIV medication for children, supporting pediatric ARV formulations development.
• Rising PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 22 July 2019Exclusive distribution partnership for US market launches including Pregabalin Capsules and other generic formulations. Rising serves as the exclusive US distributor for Laurus products.
• Global FundcoreStrategic or Co-development Partner · 26 March 2019Strategic partnership for supply of ARV combination medicines for HIV/AIDS treatment in developing nations. Laurus has previously executed major tender orders and delivered ahead of schedule for Global Fund.
• Aspen PharmacaremajorStrategic or Co-development Partner · 1 December 2018Partnership to launch improved triple combination HIV drug in South Africa. Laurus acquired Aspen's South African subsidiary (Laurus Generics SA) to strengthen African market presence.
• CASI PharmaceuticalsminorStrategic or Co-development Partner · 23 October 2018Acquisition of HBV ANDA from Laurus Labs by CASI Pharmaceuticals, transferring rights to certain generic product in US market.

Scale indicators23 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Dr. Reddy's Laboratories: Indian pharma with integrated API and finished dose operations, biologics (through subsidiary biologics business), and global generics footprint. Comparable to Laurus on integrated manufacturing, biologics/CDMO, and global regulatory track record.
• Syngene International: India's largest dedicated CDMO offering end-to-end contract development and manufacturing for small and large molecules. Highly comparable to Laurus's CDMO trajectory, innovator client base, and biologics expansion.
• Cipla: Major Indian pharma with strong ARV franchise and global HIV/AIDS supply programs. Highly comparable to Laurus on ARV API leadership, Global Fund/government procurement partnerships, and emerging market presence.
• Biocon: Indian biopharmaceutical company with biologics CDMO services and fermentation capabilities. Comparable to Laurus Bio on precision fermentation, recombinant proteins, and biologics manufacturing scale.
• Piramal Pharma: Indian pharma CDMO with strong high-potency API and contract manufacturing capabilities. Comparable to Laurus on high-potency manufacturing differentiation, CDMO services, and integrated pharma solutions.
• Cadila Healthcare (Zydus): Integrated Indian pharma with API, finished dosage, biologics, and vaccines operations. Comparable to Laurus on integrated API-to-formulation manufacturing, US market presence, and biologics ambitions.
• Divis Laboratories: Leading Indian API manufacturer with strong CDMO exposure and USFDA-inspected facilities. Directly comparable to Laurus in API scale, regulatory track record, and custom synthesis/CDMO services to global pharma innovators.
• Aurobindo Pharma: Large Indian pharma with vertically integrated API and finished dosage manufacturing, strong ARV franchise, and US generics presence. Directly comparable to Laurus in API-to-FDF integration and US market commercialization through subsidiaries.
• Lupin: Indian pharma with strong API and finished dosage manufacturing operations and US formulations presence. Comparable to Laurus on API manufacturing scale, US generic formulations, and emerging complex generics pipeline.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with specialty, generics, and API operations. Broadly comparable as an Indian pharma incumbent with global manufacturing footprint, though not a focused CDMO peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LaurusLabs
• Facebookfacebook.com/LaurusLabs
• LinkedInlinkedin.com/company/laurus-labs

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries10 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laurus Labs